Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies

Summary

This phase I clinical trial studies the safety and best dose of selumetinib and cixutumumab in treating patients with advanced solid malignancies. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry \[cancer/tumor\]-killing substances to them.

Timeline

Start

2009-11

Primary completion

2013-04

Completion

2014-09

Drugs

Indications